Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:2248-2252
Published online before print September 2, 2004, doi: 10.1161/01.STR.0000140629.65145.3c
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v36,p415)
Right arrow All Versions of this Article:
35/10/2248    most recent
01.STR.0000140629.65145.3cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallenfeldt, K.
Right arrow Articles by Fagerberg, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallenfeldt, K.
Right arrow Articles by Fagerberg, B.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Metabolic Syndrome
*Nutrition
*Obesity
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Risk Factors
Right arrow Imaging
Right arrow Lipid and lipoprotein metabolism

(Stroke. 2004;35:2248.)
© 2004 American Heart Association, Inc.


Original Contributions

Apolipoprotein B/Apolipoprotein A-I in Relation to the Metabolic Syndrome and Change in Carotid Artery Intima-Media Thickness During 3 Years in Middle-Aged Men

Karin Wallenfeldt, MD; Lena Bokemark, MD PhD; John Wikstrand, MD PhD; Johannes Hulthe, MD PhD Björn Fagerberg, MD PhD

From the Institute of Internal Medicine (K.W., L.B., B.F.) and the Wallenberg Laboratory for Cardiovascular Research (J.W., J.H., B.F.), Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden.

Correspondence to Dr Karin Wallenfeldt, Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, S-413 45 Gothenberg, Sweden. E-mail karin.wallenfeldt{at}wlab.gu.se

Background and Purpose— The apolipoprotein B (apoB)/apolipoprotein A-I (apoA-I) ratio is a measure of the relationship between different lipoprotein particles and a powerful predictor of coronary death. The aim was to examine whether apoB/apoA-I was associated with the metabolic syndrome (MetS) at baseline and also with the future change in carotid artery intima-media thickness (IMT).

Methods— In 313 58-year-old men, carotid artery IMT was measured bilaterally by high-resolution B-mode ultrasound at baseline and after 3 years of follow-up. Serum apolipoprotein concentrations and the components of MetS were measured at study entry.

Results— ApoB/apoA-I showed statistically significant associations with body mass index, waist-to-hip ratio, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein (LDL) particle size, insulin, and diastolic blood pressure. Two thirds of the patients with MetS had high apoB/apoA-I ratios (>0.90) compared with one third of those without the syndrome (P<0.001). The IMT change was associated with apoB, total cholesterol, LDL cholesterol, triglycerides, and inversely with HDL cholesterol and LDL particle size at entry, and there was a strong colinearity between these variables. The subjects with apoB/apoA-I above the first tertile (0.74) had a 20-µm-higher (95% CI, 7 to 33) annual increase in IMT compared with those below this level after adjustment for blood pressure and smoking.

Conclusions— The apoB/apoA-I ratio was strongly associated with MetS and its components at baseline. ApoB/apoA-I at baseline was related to the change in carotid artery IMT during 3 years of follow-up. There was a strong colinearity between apoB/apoA and the atherogenic lipids.


Key Words: apolipoproteins • atherosclerosis • intima-media thickness




This article has been cited by other articles:


Home page
ANGIOLOGYHome page
C. Pitsavos, D. B. Panagiotakos, J. Skoumas, L. Papadimitriou, and C. Stefanadis
Risk Stratification of Apolipoprotein B, Apolipoprotein A1, and Apolipoprotein B/AI Ratio on the Prevalence of the Metabolic Syndrome: the ATTICA Study
Angiology, July 1, 2008; 59(3): 335 - 341.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. M. M. Ooi, G. F. Watts, P. J. Nestel, D. Sviridov, A. Hoang, and P. H. R. Barrett
Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 430 - 437.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Sierra-Johnson, A. Romero-Corral, V. K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.-L. Hellenius, and R. M. Fisher
ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects
Eur. Heart J., November 1, 2007; 28(21): 2637 - 2643.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. R. Crouse III
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Lind, B. Vessby, and J. Sundstrom
The Apolipoprotein B/AI Ratio and the Metabolic Syndrome Independently Predict Risk for Myocardial Infarction in Middle-Aged Men
Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 406 - 410.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
M. Rizzo and K. Berneis
Low-density lipoprotein size and cardiovascular risk assessment
QJM, January 1, 2006; 99(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Walldius and I. Jungner
Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy
Eur. Heart J., February 1, 2005; 26(3): 210 - 212.
[Full Text] [PDF]